Dr. Choueiri on the Role of Cabozantinib in RCC

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma (RCC).

There is potential for cabozantinib to be an option in the frontline setting for patients with RCC, states Choueiri.In the results of the phase II CABOSUN trial, cabozantinib showed superiority in progression-free survival (PFS).

It could become an option for patients with intermediate and poor-risk RCC that are completely untreated and systemic therapy naïve, explains Choueiri.